ArticleInternational journal of molecular medicine2026
Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer.
Eunsun Jung et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.